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INTRODUCTION
Valvular involvement in heart disease results in stenosis,
insufficiency, or both, and the most common cause of mitral
stenosis is chronic rheumatic heart disease (1, 2). Rheumatic
fever (RF) is the consequence of a pharyngeal infection with
group A streptococcus in a susceptible host, leading to autoim-
mune disease induced by antigen mimicry of human cardiac
myosin with the streptococcal glycoprotein (3). While most
disease manifestations are transient and leave no residua,
rheumatic carditis can lead to chronic rheumatic heart dis-
ease (CRHD), which is characterized by fibrotic valvular
deformity and can produce permanent and severe cardiac dys-
function even decades later (1). 
The current hypothesis of CRHD is that fibrotic valvular
deformity evolves through organization of acute inflamma-
tion induced by RF, with subsequent thickening and retrac-
tion of valvular leaflets, and with secondary damage result-
ing from turbulent flow induced by valvular dysfunction (1,
4). There are some evidences that CRHD is associated with
ongoing inflammation of valvular leaflets. The plasma con-
centrations of TNF- and high sensitive C-reactive protein
(CRP) are significantly higher in CRHD than in controls (5-
7). It has been shown that lymphocytes obtained from CRHD
patients exhibit T helper 2 (Th2) type cytokine response
whereas those from RF patients show T helper 1 (Th1) cyto-
kine profile in cell culture with streptococcal superantigen
(8). The Th2 immune response is known to promote fibrot-
ic process by activating fibroblast proliferation, myofibrob-
last differentiation, extracellular matrix deposition, and trans-
forming growth factor-beta 1 (TGF- 1) production, where-
as Th1 type cytokines such as interferon- suppress these
processes (9-11).
TGF- 1 plays a critical role in matrix remodeling and in
enhancing collagen synthesis (12). Upon tissue injury, inflam-
mation occurs and many cytokines are secreted and TGF- 1
is released, promotes myofibroblast differentiation, and stim-
ulates fibroblasts and other reparative cells to proliferate and
to synthesize extracellular matrix components. Under normal
conditions this leads to provisional repair; however, with repeat-
ed injury, the increase in TGF- 1 production is sustained, lead-
ing to tissue fibrosis (13, 14). Recent studies have investigat-
ed TGF- 1 expression in diseased heart valves (15-17). Sero-
tonin, which is associated with carcinoid heart disease (18),
has been demonstrated to up-regulate TGF- 1 (15). Other
reports indicate that TGF- 1 is present within calcific aor-
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Overexpression of Transforming Growth Factor- 1 in the Valvular
Fibrosis of Chronic Rheumatic Heart Disease
For the purpose of determining the pathogenic role of transforming growth factor-
1 (TGF- 1) in the mechanism of chronic rheumatic heart disease, we evaluated
the expression of TGF- 1, proliferation of myofibroblasts, and changes in extracel-
lular matrix components including collagen and proteoglycan in 30 rheumatic mitral
valves and in 15 control valves. High TGF- 1 expression was identified in 21 cases
(70%) of rheumatic mitral valves, whereas only 3 cases (20%) of the control group
showed high TGF- 1 expression (p<0.001). Additionally, increased proliferation of
myofibroblasts was observed in the rheumatic valves. High TGF- 1 expression pos-
itively correlated with the proliferation of myofibroblasts (p=0.004), valvular fibrosis
(p< 0.001), inflammatory cell infiltration (p=0.004), neovascularization (p=0.007), and
calcification (p<0.001) in the valvular leaflets. The ratio of proteoglycan to collagen
deposition inversely correlated with TGF- 1 expression in mitral valves (p=0.040).
In conclusion, an ongoing inflammatory process, the expression of TGF- 1, and
proliferation of myofibroblasts within the valves have a potential role in the valvular
fibrosis, calcification, and changes in the extracellular matrix that lead to the scar-
ring sequelae of rheumatic heart disease.
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Accepted : 13 June 2007tic stenosis cusps and that it mediates the calcification of aor-
tic valve interstitial cells in cell culture via apoptosis (16). Addi-
tionally, in CRHD, the possibility that TGF-  1 gene poly-
morphism might play a role in determining the susceptibil-
ity to CRHD was suggested (17). 
In this study, we investigated the expression of TGF- 1
and changes in extracellular matrix components in mitral
valves affected by CRHD in order to determine the role of
TGF- 1 in the delayed valvular fibrosis and deformity caused
by CRHD.
MATERIALS AND METHODS
Patients and specimens
Rheumatic mitral valves were obtained from pathology
slides of 30 patients with CRHD who underwent valve remo-
val and prosthetic valve replacement surgery carried out from
2002 to 2003 in Severance Hospital, Yonsei University Col-
lege of Medicine, Seoul, Korea. These patients showed typi-
cal echocardiographic and gross findings of CRHD. Cases
complicated with infectious endocarditis or collagen vascu-
lar disease were excluded. The age of the patients ranged
from 25 to 74 yr (mean, 49.7 yr old), with 13 males and 17
females. The number of patients having mitral stenosis was
15, those with mitral regurgitation were 5, and those with
both mitral stenosis and regurgitation were 10. Twenty-three
patients demonstrated multiple valve involvement.
Normal heart valves were obtained from autopsies (14
cases) and from the removed heart of a transplantation recip-
ient (1 case), with the diagnosis of dilated cardiomyopathy
with Marfan syndrome but without definite valvular abnor-
mality. The age of the patients ranged from 12 to 73 yr (mean,
39.9 yr), with 12 males and 3 females. The hearts obtained
at autopsy were devoid of any abnormal findings except mild
thickening of valvular leaflets in three cases. The causes of
death were not heart-related. Specimens were fixed in 10%
buffered formalin and embedded in paraffin. Serial sections
were stained with hematoxylin and eosin for general mor-
phology. 
Pathologic examination
Pathologic examination of sections was carried out blind-
ed to the clinical diagnosis. The status of valvular architec-
ture was evaluated in comparison to the well established
histology offered by the normal valves. The extent of fibro-
sis, the degree of inflammatory infiltrates and neovascular-
ization, and the presence of patchy necrosis, calcification, and
thrombus attachment in valvular leaflets were examined. The
extent of fibrosis was semiquantitatively graded as follows:
no change (-); mild fibrosis without architectural distortion:
(1+); moderate fibrosis with architectural distortion: (2+);
severe fibrosis obliterating the valvular architecture (3+). The
inflammatory infiltrates was graded as follows: no inflamma-
tion: (-); scanty amount of inflammatory cell infiltration in the
stroma: (1+); and moderate inflammatory cell infiltration: (2+).
The cases showing severe inflammation in the stroma and endo-
cardial surface of the valvular leaflets were excluded in this study.
The degree of neovascularization was graded as: no change:
(-); presence of several thin-walled vessels: (1+); presence of
a few muscularized vessels: (2+); and presence of aggregates
of muscularized and ectatic thin-walled vessels: (3+). Myxoid
degeneration of valvular leaflets was scored as follows: <5%:
(-), 6-25%: (1+), 25-50%: (2+), and >50% of areas showing
myxoid degeneration in any low-power field: (3+). 
Characterization of extracellular matrix deposition in
valvular leaflets
Histochemical evaluation was performed for connective
tissue elements with Movat pentachrome stain, which differ-
entially stains collagen, elastin, and proteoglycans, to evalu-
ate the architectural distortion, alcian blue (pH 2.0) to stain
for proteoglycans, and Sirius red to stain for collagen, accord-
ing to previously described methods. The slides stained with
Movat pentachrome and alcian blue were examined under
light microscope, and the sections stained with Sirius red
were observed under polarizing microscope. Analysis of the
extent of alcian blue and Sirius red staining was performed
with a personal computer-based quantitative 24-bit (16.2
million unique combinations) color image analysis system
(KS400, Ver. 2.0, Zeiss, Germany). The slides were scanned,
negative background (black) was chosen for the threshold
and the positive area was calculated by subtraction. The same
threshold was applied to all specimens. The percentage of the
total area with positive color for each section was recorded.
Immunohistochemistry
Paraffin-embedded tissues were sectioned in 4- m slices.
Sections were preincubated with 3% hydrogen peroxide, and
antibodies against TGF- 1 (Serotec, Oxford, U.K.), vimentin
(M7020, Dako Cytomation, Glostrup, Denmark), alpha-sm-
ooth muscle actin (SMA) (Dako Cytomation), CD3 (Novo-
castra, Newcastle, U.K.), CD20 (BD Pharmingen, San Diego,
CA, U.S.A.), and CD68 (Dako Cytomation) were applied and
incubated for 60 min at room temperature. Sections were incu-
bated with biotinylated secondary antibody (Cap-plus kit,
Zymed, San Francisco, CA, U.S.A.) for 30 min and then incu-
bated with horseradish peroxidase-labelled streptavidin solu-
tion (Cap-plus kit, Zymed) for 30 min. Slides were rinsed in
phosphate-buffered saline (pH 7.4) after each incubation step.
Peroxidase activity was revealed by diaminobenzidine. Slides
were counterstained with hematoxylin and mounted. Posi-
tive reaction for TGF- 1 was semi-quantitatively evaluated
according to the extent of positive stromal area in any low-
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and >25%: high expression. The proliferation of myofibrob-
lasts was graded according to the extent of SMA-positive myofi-
broblasts among valvular interstitial cells as: <5%: negative,
5 to 25%: low, and >25%: high degree.
Statistical analysis
Statistical analysis was performed using the PC-SPSS pro-
gram (Ver 11.0, IL, U.S.A.). The data were calculated as
mean±standard deviation when available. Fisher’s exact
test was used to analyze the data obtained from immunohis-
tochemical findings, and the non-parametric Mann-Whit-
ney U test was employed to evaluate the association of TGF-
1 expression with the deposition of proteoglycan and col-
lagen. A p value less than 0.05 was considered to be statisti-
cally significant.
RESULTS
Histologic findings of rheumatic mitral valves
Histologic findings of the rheumatic mitral valves and con-
trol valves were summarized in Table 1. All control valvular
leaflets showed architectural preservation of three layers includ-
ing spongiosa, fibrosa, and ventricularis (Fig. 1A). Mild fibro-
sis was seen in three of them, mild to moderate myxoid degen-
eration in thirteen, and scanty lymphocytic infiltrates in two.
Several CD68-positive histiocytes were present in the stroma
of valve leaflets. Neovascularization, calcification, thrombus
attachment, and necrosis of the leaflets were not observed. 
By contrast, in all rheumatic mitral valves, valvular archi-
tectures were markedly distorted due to moderate-to-severe
fibrosis (Fig. 2A). Neovascularization was seen in the central
portion of the valvular leaflet in 26 cases. Six cases showed
thin-walled small vascular structures and others contained
thick muscularized vessels. Inflammatory cells infiltrated
into the perivascular stroma in 15 cases (Fig. 2B) and were
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RMV, rheumatic mitral valve; (-), negative; (+), positive.
Variables RMV (%) Control (%)
Inflammation
(-) 15 (50.0) 13 (86.7)
(1+) 13 (43.3) 2 (13.3)
(2+) 2 (6.7) 0 (0)
Neovascularization
(-) 4 (13.3) 15 (100)
(1+) 6 (20.0) 0 (0)
(2+) 10 (33.3) 0 (0)
(3+) 10 (33.3) 0 (0)
Fibrosis
(-) 0 (0) 12 (80)
(1+) 0 (0) 3 (20)
(2+) 3 (10) 0 (0)
(3+) 27 (90) 0 (0)
Myxoid degeneration
(-) 12 (40.0) 2 (13.3)
(1+) 14 (46.7) 11 (73.3)
(2+) 3 (10.0) 2 (13.3)
(3+) 1 (3.3) 0 (0)
Calcification
(-) 12 (40) 15 (100)
(+) 18 (60) 0 (0)
Architectural distortion
(-) 0 (0) 12 (80.0)
(+) 30 (100) 3 (20.0)
Patchy necrosis in the stroma
(-) 19 (63.3) 15 (100)
(+) 11 (36.7) 0 (0)
Thrombus attachment
(-) 19 (63.3) 15 (100)
(+) 11 (36.7) 0 (0)
Table 1. Histologic features of rheumatic mitral valves and con-
trol valves
Fig. 1. Histologic and immunohistochemical findings of control valves. (A) Valvular leaflets obtained from the control group showed well-pre-
served leaflet architecture without fibrosis or inflammatory cell infiltration (H&E, ×40). (B) Immunohistochemical staining for TGF- 1 demon-
strated positivity in the subendothelial stroma of valvular leaflets (TGF- 1, ×40). 
A Bpredominantly composed of CD3+ T lymphocytes. Throm-
bi were attached on the valvular leaflets in 11 cases, calcifica-
tion was noted in 18 cases, and focal necrosis was found in
the fibrotic stroma in 11 cases. Myxoid degeneration of valvu-
lar stroma was seen in 18 cases. 
In those cases showing extensive stromal fibrosis in the vavlu-
ar leaflets, more pronounced neovascularization (p<0.001),
increased inflammatory infiltrates (p=0.033), calcification (p<
0.001), stromal necrosis (p=0.004), and thrombus attachment
(p=0.009) were observed. Myxoid degeneration was seen in
areas where fibrosis or calcification was not intense.
Immunohistochemical expression of TGF- 1 and SMA
in control and rheumatic mitral valves 
In CRHD, 21 cases of rheumatic valves (70%) showed high
TGF- 1 expression, whereas only three cases of control valves
(20%) demonstrated high TGF- 1 expression (p<0.001)
(Table 2). Control valves exhibited TGF- 1 positivity on the
subendothelial stroma of valvular leaflets (Fig. 1B). On the
other hand, in CRHD, TGF- 1 was expressed in the endothe-
lial cells and smooth muscle cells of the blood vessels (13 cases),
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Fig. 2. Histologic and immunohistochemical findings of the rheumatic mitral valves. (A) Rheumatic mitral valves showed severe fibrosis and
distorted architecture (H&E, ×40). (B) A high-power view demonstrated small thin-walled vessels and perivascular lymphocytic infiltra-
tion (H&E, ×200). (C) High TGF- 1 expression was seen in the endothelial cells and smooth muscle cells of the vessels, in the perivas-
cular interstitial cells, and stroma of the valves (×200). (D) Myofibroblasts that were positive for SMA immunostaining were present in the
subendothelial densely fibrotic area (×40). 
A B
C D
RMV, rheumatic mitral valve.
TGF- 1 expression
Negative Low High
Total
p
value
RMV 0 (0%) 9 (30.0%) 21 (63.3%) 30 (100%) <0.001
Control 4 (26.7%) 8 (53.3%) 3 (20.0%) 15 (100%)
Table 2. Comparison of TGF- 1 expression between rheumatic
mitral valves and control group valves 
SMA, alpha-smooth muscle actin.
Proliferation of SMA-positive 
myofibroblasts
Negative Low High
Total
p
value
RMV 2 (6.7%) 9 (30.0%) 19 (63.3%) 30 (100%) <0.001
Control 6 (40.0%) 8 (53.3%) 1 (6.7%) 15 (100%)
Table 3. Proliferation of SMA-positive myofibroblasts in rheumatic
mitral valves and control group valvesthe interstitial cells and perivascular stroma (3 cases), or both
(14 cases) (Fig. 2C). High TGF- 1 expression correlated with
severe valvular fibrosis (p<0.001), inflammatory cell infiltra-
tion (p=0.004), neovascularization (p=0.007) and calcifica-
tion (p<0.001), but no correlation was observed between
TGF- 1 expression and myxoid degeneration (p=0.173). 
The number of SMA-positive myofibroblasts was signifi-
cantly increased in valvular leaflets of CRHD compared to
control valves (Table 3), and the proliferation of SMA-positive
myofibroblasts positively correlated with TGF- 1 expres-
sion (p=0.004) (Table 4) and fibrosis of valvular leaflets (p<
0.001). SMA-positive myofibroblasts were usually seen in
the areas showing increased collagen deposition, and in the
subendocardial stroma (Fig. 2D). 
Deposition of collagen and proteoglycan in control and
rheumatic mitral valves
Extracellular matrix deposition of proteoglycan and colla-
gen was markedly different in the CRHD and control groups.
In control valves, the proteoglycan was present in the spon-
giosa and collagen was found in the fibrosa. Whereas, in
CRHD, proteoglycan was deposited in the perivascular stro-
ma or in areas showing myxoid degeneration, and the colla-
gen was in the stroma showing dense fibrosis or myofibrob-
lastic proliferation. The proportion of alcian blue-positive
areas quantitatively calculated by image analyzer occupied a
mean of 3.75% (range 0-23.5%) of valvular matrix in CRHD,
compared to the mean of 13.2% (range 0-41.9%) in the con-
trol group (p=0.014) (Fig. 3A). The proportion of Sirius red-
positive areas, which represent type I and III collagen deposi-
tion, averaged 23% (range 8.1-51.4%) in CRHD and 11.2%
(range 5.9-22.0%) in the control group (p<0.001) (Fig. 3B).
Additionally, the ratio of proteoglycan to collagen deposition
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Fig. 3. Proteoglycan and collagen deposition in rheumatic mitral
valves and control valves. (A) The proportion of proteoglycan
deposited areas was lower in rheumatic mitral valve group (RM)
than in the control group (black bars represented mean values:
3.75% vs. 13.2%) (p=0.014). (B) The rheumatic mitral valve group
(RM) showed extensive collagen deposition compared to the con-
trol group (black bars represented mean values: 23% vs. 11.2%)
(p<0.001). (C) The ratio of proteoglycan to collagen deposited
areas was lower in the TGF- 1 positive group than in the TGF- 1
negative group (black bars represented mean values: 0.38 vs.
0.66) (p=0.040). 
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SMA, alpha-smooth muscle actin.
Proliferation of SMA-positive 
myofibroblasts TGF- 1 
expression
Negative Low High
Total
p
value
Negative 2 2 0 4
=0.004
(50%) (50%) (0%) (100%)
Low 3 9 5 17
(17.6%) (52.9%) (29.4%) (100%)
High 3 6 15 24
(12.5%) (25.0%) (62.5%) (100%)
Table 4. Proliferation of SMA-positive myofibroblasts in valvular
leaflets according to TGF- 1 expressionwas lower in the rheumatic mitral valve group than in the con-
trol valve group (p=0.001). The proportion of collagen and
proteoglycan deposition was not associated with TGF- 1 ex-
pression (p=0.34 and 0.087), but the ratio of proteoglycan to
collagen deposition was lower in the TGF- 1 positive group
than in the negative group (p=0.04) (Fig. 3C).
DISCUSSION
CRHD, the most significant complication of RF, demon-
strates severe fibrosis and distortion of valvular leaflets (1, 3).
The factors leading to continued fibrosis and subsequent valvu-
lar disease remain incompletely defined. There are consider-
able evidences to indicate that TGF- 1 overproduction plays
some role in fibrosis and dysfunction in heart valves. TGF- 1
expression is increased in carcinoid valve cusps (15), calcific
aortic valve cusps (16), and prolapsed valves in a mouse model
of Marfan syndrome (19). In cases of CRHD, TGF- 1 poly-
morphisms may predispose to valvular disease. Chou et al. de-
monstrated that patients with CRHD have a lower frequency
of the TGF- 1 C509T CC genotype and a higher frequen-
cy of the T869C T allele (17). They proposed the possibility
that TGF- 1 gene polymorphisms might play a role in deter-
mining susceptibility to CRHD. However, there has been no
study showing localized overproduction of TGF- 1 in valvu-
lar leaflets of CRHD. Our study has demonstrated high TGF-
1 expression in valvular leaflets of CRHD and might sup-
port the hypothesis that TGF- 1 overproduction would play
a role in the valvular fibrosis of CRHD.
It may be difficult to appreciate that, in valvular leaflets of
CRHD, fibrosis and remodeling is going on even several de-
cades after initial attack. There are some studies demonstrat-
ing persistent inflammation in valvular leaflets of CRHD (4,
20, 21). Lymphocytic infiltrations have been identified in valves
removed 10-20 yr after initial attacks of RF, and the predom-
inant cellular infiltrate was T lymphocytes (4). Prolonged per-
sistence of group A streptococcal carbohydrate antibody was
demonstrated in CRHD even decades later (20). Additional-
ly, the plasma concentrations of TNF- and highly sensitive
CRP are significantly higher in CRHD (5, 6, 7, 21). Accord-
ing to the study by Bhatnagar et al. (8), lymphocytes derived
from CRHD patients exhibit the Th2 type cytokine response
whereas those from RF patients show the Th1 cytokine pro-
file with response to the streptococcal superantigen. The Th2
immune response is associated with fibrotic process including
TGF- 1 secretion, whereas Th1 type cytokines suppresses
diverse fibrotic activities (9-11). Guilherme et al. (22) demon-
strated that CD4+ T cells derived from heart lesions predom-
inantly secrete Th1 type cytokines in both RF and CRHD
patients. The different results observed in these two studies
are probably due to the different characterization of CRHD
patients analysed. The study by Guilherme et al. included the
early stage of CRHD patients with age range from 10 to 20
yr, whereas the age of the patients in the study by Bhatnagar
et al. ranged from 22 to 54 yr (8, 22). Therefore, the cytokine
profiles of early stage CRHD might be similar to that of RF.
It is possible that Th2 type cytokine response seen in the ad-
vanced CRHD (8) might be induce the TGF- 1 overexpres-
sion and the fibrotic process as well as prolonged inflammation
seen in the distorted rheumatic valves. Our report confirmed
the fact that ongoing inflammation mainly composed of T
lymphocytes was present in the apparently resting valves of
advanced CRHD, and TGF- 1 expression correlated with
the degree of inflammatory infiltrates. Additionally, TGF-
1 expression was present predominantly in the perivascular
stroma where inflammatory cells mainly infiltrated. These
results support the hypothesis that a continued inflammato-
ry process and overproduction of TGF- 1 within the valves
of the susceptible hosts would lead to the prolonged fibrosis
of valvular leaflets in advanced CRHD.
TGF- 1 induces the differentiation of cardiac fibroblasts
to myofibroblasts (24), which can produce up to twice as
much collagen as their fibroblast precursors (25). The emer-
gence of these cells has been closely correlated with valvular
fibrosis and degenerative lesions (26). Our study demonstrat-
ed that increased proliferation of myofibroblasts was observed
in the rheumatic valves without alteration of cellularity of
valvular interstitial cells and that high TGF- 1 expression
was related to the proliferation of myofibroblasts and calcifica-
tion of valvular leaflets. Calcific aortic stenosis cusps demon-
strate higher concentrations of TGF- 1 within the extracel-
lular matrix compared with noncalcified cusps (16). When
cultured interstitial cells are exposed to TGF- 1 for a long
period of time, aggregates of cells evolve into nodules that
become apoptotic, express alkaline phosphatase, and then
calcify (16). Therefore, increased TGF- 1 expression in rheu-
matic heart valves may induce the differentiation of valvular
interstitial cells to the myofibroblasts and the overproduction
of extracellular matrix, resulting in progressive fibrosis and
valvular distortion, and prolonged exposure to TGF- 1 prob-
ably induces calcification of valvular leaflets seen in CRHD.
TGF- 1 is also known to play a critical role in matrix remod-
eling by enhancing collagen synthesis (12). The normal heart
valve is composed of collagen, proteoglycan and elastin, and
approximately 85% of the total collagen in the heart is type
I collagen (27). In rheumatic valves, the total amounts of col-
lagen, proteoglycan, and elastin are significantly increased (27).
Our result demonstrated that the proportion of collagen depo-
sition was increased, and proteoglycan deposition was decreased
in rheumatic valvular leaflets compared to control valves, but
that it did not correlate with TGF- 1 overexpression. Because
only the percentage of collagen and proteoglycan deposited
areas in the valvular leaflets was evaluated and the total amount
of collagen was not calculated, we were unable to investigate
the accurate relationship of collagen deposition to TGF- 1
expression. However, the ratio of proteoglycan to collagen
deposited areas was lower in the TGF- 1 positive group than
46 L. Kim, D.K. Kim, W.I. Yang, et al.in the negative group. Therefore TGF- 1 expression might
be related to the conversion of extracellular matrix from pro-
teoglycan to collagen rather than to the percentage of colla-
gen or that of proteoglycan.
There are a number of efforts that have aimed to reduce fibro-
sis in cardiovascular disease, such as post-ischemic fibrosis, and
dilated and hypertrophic cardiomyopathies, and targeting the
TGF- 1 may be effective in attenuating fibrosis and hypertro-
phy in the heart (26). Our study indicated that TGF- 1 may
play some role in valvular fibrosis and deformity in CRHD,
and therefore, TGF- 1 might be an appropriate target for
prevention of subsequent valvular dysfunction in patients
having suffered from RF.
In conclusion, TGF- 1 expression is increased in rheumatic
mitral valves, and higher TGF- 1 expression is associated
with valvular fibrosis, inflammatory cell infiltration, differ-
entiation of valvular fibroblasts to myofibroblasts, calcifica-
tion, and changes in the extracellular matrix in the valves of
CRHD. These results support the hypothesis that TGF- 1
expression might play some role in the prolonged fibrosis
and severe valvular deformity typical of CRHD. 
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